Efficacy and safety of two dosages of canrenone as add‐on therapy in hypertensive patients taking ace‐inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The ESCAPE‐IT trial

AIM: To evaluate the effects of canrenone as add‐on therapy in patients already treated with angiotensin‐converting enzyme inhibitors (ACE‐I) or angiotensin II receptor blockers (ARBs) and hydrochlorothiazide at the maximum dosage (25 mg/d). METHOD: In this randomized, open‐label, controlled trial,...

Descripción completa

Detalles Bibliográficos
Autores principales: Derosa, Giuseppe, Maffioli, Pamela, D'Avino, Maria, Sala, Carla, Mugellini, Amedeo, Vulpis, Vito, Felis, Salvatore, Guasti, Luigina, Sarzani, Riccardo, Bestetti, Alessandro, Vanasia, Massimo, Gaudio, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6680336/
https://www.ncbi.nlm.nih.gov/pubmed/27860389
http://dx.doi.org/10.1111/1755-5922.12235

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6680336/
https://www.ncbi.nlm.nih.gov/pubmed/27860389
http://dx.doi.org/10.1111/1755-5922.12235

Ejemplares similares